首页> 美国卫生研究院文献>Malaria Research and Treatment >Efficacy of Eosin B as a New Antimalarial Drug in a Murine Model
【2h】

Efficacy of Eosin B as a New Antimalarial Drug in a Murine Model

机译:曙红B作为一种新的抗疟疾药物在小鼠模型中的功效。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The initial success of any adopted anti-infective strategy to malaria is followed by a descent due to the emergence of resistance to it. The search for new drugs and drug targets is a consistent demand in this disease. Eosin B, a common laboratory dye, is reported to have good antiparasitic properties in vitro. It was studied for its antiparasitic effect in vivo on chloroquine-sensitive Plasmodium berghei murine malaria. Eosin B was administered in 2 different doses by either the oral or parenteral route, once or twice daily to mice infected with Plasmodium berghei. Both the doses of eosin B 400 mg/kg and 800 mg/kg gave better results than the controls which were 40 mg/kg chloroquine and 100 mg/kg of arteether with P < 0.005 significance. Percentage suppressive activity by Peter's test of eosin B was better, though at a higher dose than both the controls. Survival rate of mice receiving the higher dose of eosin B was longer than that of the controls. When administered twice daily, the mice were fully cured after 4 days. Eosin B seems to be a promising drug exhibiting good antimalarial effects in the murine model of the disease.
机译:任何对疟疾采取的抗感染策略的最初成功都是由于对疟疾的抗药性下降。寻找新药和新药靶标是对这种疾病的持续需求。据报道,曙红B是一种常见的实验室染料,在体外具有良好的抗寄生虫特性。研究了其对氯喹敏感的伯氏疟原虫鼠疟疾的体内抗寄生虫作用。曙红B通过口服或肠胃外途径以2种不同剂量给药,每天一次或两次给予感染了伯氏疟原虫的小鼠。曙红B400μmg/ kg和800μmg/ kg的剂量均比对照组40μmg/ kg氯喹和100μmg/ kg的蒿甲醚有更好的结果,P <0.005的意义。通过彼得氏法测试曙红B的抑制活性更好,尽管剂量高于两个对照组。接受更高剂量曙红B的小鼠的存活率比对照组更长。当每天两次给药时,小鼠在4天后完全治愈。曙红B似乎是一种有前途的药物,在该疾病的小鼠模型中表现出良好的抗疟作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号